Literature DB >> 16207259

Mortality risk factors of Acinetobacter baumannii bacteraemia.

J Y Choi1, Y S Park, C O Kim, Y S Park, H J Yoon, S Y Shin, Y-A Kim, Y G Song, D Yong, K Lee, J M Kim.   

Abstract

BACKGROUND: Acinetobacter baumannii is one of the most important nosocomial pathogens, and its multiple antibiotic resistance has emerged as an obstacle in the treatment of these infections worldwide. AIMS: To identify risk factors of mortality for A. baumannii bacteraemia.
METHODS: A retrospective cohort study of 72 patients with significant A. baumannii bacteraemia was conducted to evaluate risk factors for mortality.
RESULTS: The median age of the 72 enrolled patients was 48 years, 96% of the cases were hospital-acquired, and the bacteraemia-related mortality rate was 29% (21 of 72 patients). Univariate analysis revealed that the risk factors for mortality included: an elevated acute physiology and chronic health evaluation (APACHE II) score, receipt of in vitro ineffective definitive antimicrobial therapy, in vitro A. baumannii resistance to cefoperazone/ sulbactam, neutropenia, and presentation with septic shock. Multivariate analysis reveals that the independent risk factors for mortality are neutropenia and elevated APACHE II scores.
CONCLUSION: Risk factors such as neutropenia and elevated APACHE II scores are found to be associated with higher mortality rates of A. baumannii bacteraemia. Further study is necessary for the determination of optimal strategies for both the prevention and treatment of these infections.

Entities:  

Mesh:

Year:  2005        PMID: 16207259     DOI: 10.1111/j.1445-5994.2005.00925.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  20 in total

1.  Empirical antibiotic therapy of sepsis in surgical intensive care unit.

Authors:  Ljiljana Mihaljević; Slobodan Mihaljević; Ivan Vasilj; Semra Cavaljuga; Fadila Serdarević; Ivan Soldo
Journal:  Bosn J Basic Med Sci       Date:  2007-08       Impact factor: 3.363

2.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

3.  Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii.

Authors:  Dror Marchaim; Shiri Navon-Venezia; David Schwartz; Jalal Tarabeia; Iris Fefer; Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Clin Microbiol       Date:  2007-02-21       Impact factor: 5.948

4.  Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.

Authors:  D W Wareham; D C Bean; P Khanna; E M Hennessy; D Krahe; A Ely; M Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 3.267

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Molecular Detection of Adefg Efflux Pump Genes and their Contribution to Antibiotic Resistance in Acinetobacter baumannii Clinical Isolates.

Authors:  Rasoul Kaviani; Iman Pouladi; Mohammad Niakan; Reza Mirnejad
Journal:  Rep Biochem Mol Biol       Date:  2020-01

7.  The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections.

Authors:  Seung-Kwan Lim; Sang-Oh Lee; Seong-Ho Choi; Jae-Phil Choi; Sung-Han Kim; Jin-Yong Jeong; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim
Journal:  J Korean Med Sci       Date:  2011-02-25       Impact factor: 2.153

8.  Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia.

Authors:  Se Yoon Park; Jin Woo Choo; Soon Ha Kwon; Shi Nae Yu; Eun Jung Lee; Tae Hyong Kim; Eun Ju Choo; Min Huok Jeon
Journal:  Infect Chemother       Date:  2013-09-27

9.  Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia.

Authors:  Mirjana Lulic-Botica; Lilia Dejesus
Journal:  AJP Rep       Date:  2011-01-24

10.  Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Authors:  Youn Jeong Kim; Sang Il Kim; Kyung-Wook Hong; Yang Ree Kim; Yeon Joon Park; Moon-Won Kang
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.